Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A synthetic small molecule belonging to the class of 6‑aminopurines, characterized by a butyl group at position 9, a (4‑methoxybenzyl) group at position 8, and an amino group at position 6 on the purine ring. It is an experimental compound with no approved medical indications or marketed formulations. The primary mechanism of action is inhibition of heat shock protein HSP90-alpha (HSP90AA1), a molecular chaperone involved in protein folding and stabilization. By inhibiting HSP90-alpha, this compound may disrupt cellular stress responses and has been investigated as a research tool for studying chaperone biology[1][3][7]. No clinical trials or therapeutic uses are reported.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 9-butyl-8-(4-methoxybenzyl)-9h-purin-6-amine.